Michael John Tomsicek - Jun 13, 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Director
Signature
/s/ Adam D. Levy, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
Jun 13, 2025
Transactions value $
$0
Form type
4
Date filed
6/17/2025, 05:57 PM
Previous filing
Jun 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
TOMSICEK MICHAEL JOHN Director C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Adam D. Levy, Attorney-in-Fact 2025-06-17 0001570392

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Award $0 +20.3K $0.00 20.3K Jun 13, 2025 Common Stock 20.3K $1.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney